A detailed history of Rafferty Asset Management, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 63,831 shares of ALNY stock, worth $15.7 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
63,831
Previous 81,110 21.3%
Holding current value
$15.7 Million
Previous $19.7 Million 10.91%
% of portfolio
0.06%
Previous 0.07%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$233.81 - $287.01 $4.04 Million - $4.96 Million
-17,279 Reduced 21.3%
63,831 $17.6 Million
Q2 2024

Aug 13, 2024

BUY
$143.31 - $247.0 $2.85 Million - $4.92 Million
19,904 Added 32.52%
81,110 $19.7 Million
Q1 2024

May 13, 2024

BUY
$146.51 - $198.2 $1.23 Million - $1.66 Million
8,398 Added 15.9%
61,206 $9.15 Million
Q4 2023

Feb 13, 2024

BUY
$151.41 - $196.57 $1.31 Million - $1.7 Million
8,640 Added 19.56%
52,808 $10.1 Million
Q3 2023

Nov 13, 2023

BUY
$170.77 - $211.65 $105,023 - $130,164
615 Added 1.41%
44,168 $7.82 Million
Q2 2023

Aug 11, 2023

BUY
$185.01 - $212.05 $992,023 - $1.14 Million
5,362 Added 14.04%
43,553 $8.27 Million
Q1 2023

May 11, 2023

BUY
$182.66 - $235.53 $344,862 - $444,680
1,888 Added 5.2%
38,191 $7.65 Million
Q4 2022

Feb 13, 2023

BUY
$185.53 - $241.31 $632,842 - $823,108
3,411 Added 10.37%
36,303 $8.63 Million
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $235,795 - $394,864
1,702 Added 5.46%
32,892 $6.58 Million
Q2 2022

Aug 12, 2022

SELL
$120.42 - $169.29 $703,854 - $989,500
-5,845 Reduced 15.78%
31,190 $4.55 Million
Q1 2022

May 13, 2022

BUY
$127.18 - $173.91 $647,346 - $885,201
5,090 Added 15.93%
37,035 $6.05 Million
Q4 2021

Feb 10, 2022

BUY
$159.56 - $209.29 $2.48 Million - $3.25 Million
15,515 Added 94.43%
31,945 $5.42 Million
Q3 2021

Nov 10, 2021

BUY
$169.75 - $207.73 $105,414 - $129,000
621 Added 3.93%
16,430 $3.1 Million
Q2 2021

Aug 10, 2021

SELL
$128.63 - $176.89 $980,031 - $1.35 Million
-7,619 Reduced 32.52%
15,809 $2.68 Million
Q1 2021

May 10, 2021

BUY
$126.83 - $175.69 $2.06 Million - $2.85 Million
16,239 Added 225.89%
23,428 $3.31 Million
Q4 2020

Feb 10, 2021

SELL
$122.97 - $147.0 $1.11 Million - $1.33 Million
-9,017 Reduced 55.64%
7,189 $934,000
Q3 2020

Nov 13, 2020

BUY
$121.19 - $165.49 $759,012 - $1.04 Million
6,263 Added 62.99%
16,206 $2.36 Million
Q2 2020

Aug 07, 2020

BUY
$104.21 - $156.44 $610,983 - $917,207
5,863 Added 143.7%
9,943 $1.47 Million
Q1 2020

May 15, 2020

SELL
$93.12 - $133.99 $2.74 Million - $3.94 Million
-29,417 Reduced 87.82%
4,080 $444,000
Q4 2019

Feb 10, 2020

SELL
$74.51 - $124.23 $3.29 Million - $5.48 Million
-44,138 Reduced 56.85%
33,497 $3.86 Million
Q3 2019

Nov 14, 2019

BUY
$70.9 - $87.82 $486,232 - $602,269
6,858 Added 9.69%
77,635 $6.24 Million
Q2 2019

Aug 09, 2019

BUY
$65.86 - $92.79 $727,884 - $1.03 Million
11,052 Added 18.5%
70,777 $5.14 Million
Q1 2019

May 15, 2019

BUY
$72.76 - $93.45 $4.35 Million - $5.58 Million
59,725 New
59,725 $5.58 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.2B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.